NasdaqGM - Delayed Quote USD

CRISPR Therapeutics AG (CRSP)

56.41 +0.75 (+1.35%)
At close: April 23 at 4:00 PM EDT
57.59 +1.18 (+2.09%)
Pre-Market: 5:57 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
370,000.00
370,000.00
436.00
913,081.00
543.00
Cost of Revenue
130,250.00
130,250.00
110,250.00
101,178.00
--
Gross Profit
239,750.00
239,750.00
-109,814.00
811,903.00
--
Operating Expense
462,288.00
462,288.00
563,347.00
438,375.00
354,978.00
Operating Income
-222,538.00
-222,538.00
-673,161.00
373,528.00
-354,435.00
Other Income Expense
71,816.00
71,816.00
22,661.00
6,003.00
6,379.00
Pretax Income
-150,722.00
-150,722.00
-650,500.00
379,531.00
-348,056.00
Tax Provision
2,888.00
2,888.00
-325.00
1,870.00
809.00
Net Income Common Stockholders
-153,610.00
-153,610.00
-650,175.00
377,661.00
-348,865.00
Diluted NI Available to Com Stockholders
-153,610.00
-153,610.00
-650,175.00
377,661.00
-348,865.00
Basic EPS
-1.94
-1.94
-8.36
4.97
-5.29
Diluted EPS
-1.94
-1.94
-8.36
4.70
-5.29
Basic Average Shares
79,220.93
79,220.93
77,746.58
75,948.69
65,949.67
Diluted Average Shares
79,220.93
79,220.93
77,746.58
80,393.50
65,949.67
Total Operating Income as Reported
-222,538.00
-222,538.00
-673,161.00
373,528.00
-354,435.00
Total Expenses
592,538.00
592,538.00
673,597.00
539,553.00
354,978.00
Net Income from Continuing & Discontinued Operation
-153,610.00
-153,610.00
-650,175.00
377,661.00
-348,865.00
Normalized Income
-153,610.00
-153,610.00
-650,175.00
377,661.00
-348,865.00
EBIT
-222,538.00
-222,538.00
-673,161.00
373,528.00
-354,435.00
EBITDA
-202,701.00
-202,701.00
-648,989.00
391,481.00
-345,251.00
Reconciled Cost of Revenue
130,250.00
130,250.00
110,250.00
101,178.00
--
Reconciled Depreciation
19,837.00
19,837.00
24,172.00
17,953.00
9,184.00
Net Income from Continuing Operation Net Minority Interest
-153,610.00
-153,610.00
-650,175.00
377,661.00
-348,865.00
Normalized EBITDA
-202,701.00
-202,701.00
-648,989.00
391,481.00
-345,251.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 10/19/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NTLA Intellia Therapeutics, Inc.
21.53
-1.37%
 
EDIT Editas Medicine, Inc.
5.46
-2.50%
 
VRTX Vertex Pharmaceuticals Incorporated
404.91
+1.25%
 
BEAM Beam Therapeutics Inc.
23.47
-2.61%
 
VKTX Viking Therapeutics, Inc.
64.93
+1.69%
 
BLUE bluebird bio, Inc.
0.9706
+1.78%
 
DNA Ginkgo Bioworks Holdings, Inc.
0.8705
+3.29%
 
RXRX Recursion Pharmaceuticals, Inc.
7.70
+1.32%
 
MRNA Moderna, Inc.
107.89
+3.28%
 
NVO Novo Nordisk A/S
128.64
+2.70%